Compound
D1045 | phenazopyridine hydrochloride
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 15.72±3.45 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | human | HepG2 | MMP assay | Negative | IC50 | 163 | ||
| MEMBRANE POTENTIAL | 23.75±1.93 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Warning |
Aggregated GHS information provided by 77 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (94.81%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (94.81%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H335 (93.51%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure Respiratory tract irritation] H351 (100%): Suspected of causing cancer [Warning Carcinogenicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
|
|
Danger |
H302: Harmful if swallowed [Warning Acute toxicity, oral] H341: Suspected of causing genetic defects [Warning Germ cell mutagenicity] H351: Suspected of causing cancer [Warning Carcinogenicity] H370: Causes damage to organs [Danger Specific target organ toxicity, single exposure] H373: Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] |
P201, P202, P260, P264, P270, P281, P301+P312, P307+P311, P308+P313, P314, P321, P330, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| women | TDLo | oral | 140mg/kg (140mg/kg) | Canadian Medical Association Journal. Vol. 91, Pg. 756, 1964. | |
| man | TDLo | oral | 114mg/kg (114mg/kg) | Human Toxicology. Vol. 2, Pg. 539, 1983. | |
| child | TDLo | oral | 125mg/kg (125mg/kg) | Clinical Pediatrics Vol. 10, Pg. 537, 1971. | |
| child | TDLo | oral | 35mg/kg (35mg/kg) | American Journal of Diseases of Children. Vol. 117, Pg. 369, 1969. | |
| rat | LD50 | oral | 472mg/kg (472mg/kg) | Toxicology and Applied Pharmacology. Vol. 1, Pg. 42, 1959. | |
| rat | LDLo | intraperitoneal | 200mg/kg (200mg/kg) | Journal of Pharmacology and Experimental Therapeutics. Vol. 51, Pg. 200, 1934. | |
| women | TDLo | oral | 34mg/kg (34mg/kg) | Annals of Internal Medicine. Vol. 72, Pg. 89, 1970. | |
| man | TDLo | oral | 86mg/kg/10D-I (86mg/kg) | spinal cord: inflammatory changes | Annals of Internal Medicine. Vol. 106, Pg. 164, 1987. |
| mouse | LD50 | intravenous | 180mg/kg (180mg/kg) | U.S. Army Armament Research & Development Command, Chemical Systems Laboratory, NIOSH Exchange Chemicals. Vol. NX#04014, | |
| child | TDLo | oral | 400mg/kg (400mg/kg) | American Journal of Diseases of Children. Vol. 110, Pg. 105, 1965. | |
| (E)-3-(phenyldiazenyl)pyridine-2,6-diamine hydrochloride | .beta.-Phenylazo-.alpha.,.alpha.'-diaminopyridine hydrochloride | 0EWG668W17 |
| 136-40-3 | 2, 3-(phenylazo)-, monohydrochloride | 2,6-DIAMINO-3-(PHENYLAZO)-PYRIDINE HYDROCHLORIDE |
| 2,6-Diamino-3-(phenylazo)pyridine hydrochloride | 2,6-Diamino-3-(phenylazo)pyridine monohydrochloride | 2,6-Diamino-3-phenylazopyridine hydrochloride |
| 2,6-Pyridinediamine, 3-(2-phenyldiazenyl)-, hydrochloride (1:1) | 2,6-Pyridinediamine, 3-(phenylazo)-, monohydrochloride | 3-(2-phenyldiazen-1-yl)pyridine-2,6-diamine hydrochloride |
| 3-(Phenylazo)-2,6-diaminopyridine hydrochloride | 3-(Phenylazo)-2,6-pyridinediamine hydrochloride | 3-(Phenylazo)-2,6-pyridinediamine, hydrochloride |
| 3-(phenylazo)-2,6-pyridinediamine monohydrochloride | 3-(phenyldiazenyl)pyridine-2,6-diamine hydrochloride | 3-Phenylazo-2,6-diaminopyridine Monohydrochloride |
| 3-Phenylazo-2,6-diaminopyridine hydrochloride | 3-Phenylazo-2,6-diaminopyridine hydrochloride (Phenazopyridine hydrochloride) | 3-[(E)-2-phenyldiazen-1-yl]pyridine-2,6-diamine hydrochloride |
| 3-[(E)-phenyldiazenyl]pyridine-2,6-diamine hydrochloride | 3-[(E)-phenyldiazenyl]pyridine-2,6-diamine;hydrochloride | 3-[phenyldiazenyl]pyridine-2,6-diamine hydrochloride |
| AC-2036 | ACMC-209c5v | AI3-51273 |
| AKOS015919909 | AKOS025401514 | ANW-20033 |
| Azo-Mandelamine | Azo-Standard | Azodyne |
| Azomine | Azosulfisox | B0022 |
| BIM-0051479.0001 | BR-30240 | Bisteril |
| C11H11N5.HCl | C19290 | CAS-136-40-3 |
| CCG-39935 | CCRIS 497 | CHEBI:71419 |
| CHEMBL1201022 | CHEMBL1606101 | CP0138 |
| CS-4476 | CTK8B0470 | D05450 |
| DSSTox_CID_1118 | DSSTox_GSID_21118 | DSSTox_RID_75950 |
| DTXSID1021118 | Di-Azo | Diridone |
| Dolonil | EINECS 205-243-8 | FT-0603345 |
| HMS1570G06 | HMS1920F18 | HY-B0985 |
| KS-000000R2 | KS-1427 | KSC910I7B |
| LS-793 | MCULE-1193471524 | MFCD00035347 |
| MLS000069507 | MLS001074123 | MLS002222176 |
| Mallofeen | Mallophene | NC 150 |
| NC-150 | NCGC00018130-04 | NCGC00018130-09 |
| NCGC00091334-01 | NCGC00091334-03 | NCGC00094755-01 |
| NCGC00094755-02 | NCGC00094755-03 | NCGC00094755-04 |
| NCGC00256528-01 | NCGC00259702-01 | NCI-C01672 |
| NSC 1879 | NSC-1879 | NSC-227115 |
| NSC-757267 | NSC1879 | NSC227115 |
| NSC757267 | Nefrecil | Opera_ID_1284 |
| Pharmakon1600-01500473 | Phenazodine | Phenazopyridine (hydrochloride) |
| Phenazopyridine HCl | Phenazopyridine M hydrochloride | Phenazopyridine hydrochloride |
| Phenazopyridine hydrochloride (USP) | Phenazopyridine hydrochloride [USAN:USP] | Phenazopyridine hydrochloride [USAN] |
| Phenazopyridine hydrochloride(USAN) | Phenazopyridine hydrochloride, 99%, analytical standard | Phenazopyridine hydrochloride, United States Pharmacopeia (USP) Reference Standard; |
| Phenazopyridine hydrochloride, VETRANAL(TM), analytical standard | Phenazopyridine.HCl | Phenazopyridinium chloride |
| Phenyl-idium | Phenyl-idium 200 | Phenylazo tablets |
| Phenylazo-.alpha.,.alpha.'-diaminopyridine monohydrochloride | Phenylazo-alpha,alpha'-diaminopyridine monohydrochloride | Phenylazodiaminopyridine hydrochloride |
| Phenylazopyridine hydrochloride | Pirid | Prestwick_158 |
| Pyrazodine | Pyri-Pyridium | Pyridacil |
| Pyridiate | Pyridine, 2,6-diamino-3-(phenylazo)-, hydrochloride | Pyridine, 2,6-diamino-3-(phenylazo)-, monohydrochloride |
| Pyridine,6-diamino-3-(phenylazo)-, hydrochloride | Pyridine,6-diamino-3-(phenylazo)-, monohydrochloride | Pyridium |
| Pyridivite | Pyripyridium | Pyrizin |
| Q27139594 | QQBPIHBUCMDKFG-UHFFFAOYSA-N | RTR-004871 |
| S-1578 | SC-23554 | SCHEMBL19357 |
| SMR000058632 | SPECTRUM1500473 | SR-05000001695 |
| SR-05000001695-2 | ST2410390 | ST50410261 |
| SW196469-3 | Sedural | Suladyne |
| Thiosulfil-A | Thiosulfil-A forte | Tox21_110829 |
| Tox21_110829_1 | Tox21_202153 | Tox21_302738 |
| UNII-0EWG668W17 | Urazium | Uridinal |
| Uriplex | Urodine | VP13659 |
| W 1655 | W 6155 | W-108251 |
| W-1655 | WLN: T6NJ BZ CNUNR & FZ & GH | azo gantrisin |
| azo gastanol | azo-stat | azodine |
| azodium | beta-phenylazo-alpha,alpha'-diaminopyridine hydrochloride | component of Azo Gantanol |
| component of Azo-Mandelamine | component of Azotrex | component of Dolonil |
| component of Sulfid | cystamine 'mcclung ' | cystamine 'mcclung' |
| cystopyrin | giracid | p yridene |
| phen ylazo-alpha,alpha'-diaminopyridine monohydrochloride | phenazopyridine monohydrochloride | phenazopyridine-hcl |
| phenylazo | pyredal | pyridenal |
| pyridene | s4235 | sulodyne |
| urofeen | uromide | uropyridin |
| uropyrine | utos tan | utostan |
| vestin |